PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH)...
Hence then, the article about ribox therapeutics announces first patient dosed in phase i iia clinical trial of rxrg001 the first circular rna therapy for the treatment of radiation induced xerostomia and hyposalivation was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation )
Also on site :
- Everything New on HBO Max in November 2026, From ‘The Gilded Age’ Season 4 to ‘Elf’ and More Holiday Favorites
- ‘DWTS’ Guest Judge Shirley Ballas Defends Her Historically Low Scores After Horror Movie Night
- Kenny Loggins, 78, Just Hit the Red Carpet With His New Wife Lisa, and She’s a Stunning Blonde Beauty